Active	Status	Sponsor type	Region	Phase	Filter
6 Active 0 Inactive 6 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   - « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   Show only changed items Enrollment:

Advanced Filters

6 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Tosi, Patrizia
SELECT MDS-1, NCT04797780 / 2020-004528-40: Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome	Terminated	3	246	Europe, Canada, US, RoW	Tamibarotene, SY-1425, Placebo, Azacitidine	Syros Pharmaceuticals	Myelodysplastic Syndromes	11/24	11/24
KRdvsRd, NCT04096066: A Trial That Compare Two Treatments in Newly Diagnosed Myeloma Patients Not Eligible for Transplant	Active, not recruiting	3	84	Europe	Carfilzomib, Kyprolis, Lenalidomide, Revlimid, Dexamethasone	Fondazione EMN Italy Onlus	Multiple Myeloma, New Diagnosis Tumor	01/26	01/26
DREAMM 14, NCT05064358 / 2021-004151-16: Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma Jul 2024 - Dec 2024 : Data for RRMM	Active, not recruiting	2	177	Europe, Canada, US, RoW	Belantamab mafodotin	GlaxoSmithKline	Multiple Myeloma	08/24	01/26
AL-TOMICA, NCT06626893: Integrative "Omics" Approaches for Leukemia Target Identification and Matched Therapeutic Intervention	Recruiting	N/A	100	Europe	Functional tests, Next Generation Sequencing analysis, Microvesicles analysis	Azienda Ospedaliero-Universitaria di Parma	Myeloid Leukemia, Acute, Leukemia, Acute Lymphoblastic	03/25	03/25
NCT04352556: COVID19-hematological Malignancies: the Italian Hematology Alliance	Recruiting	N/A	250	Europe		Ospedale di Circolo - Fondazione Macchi	SARS-CoV-2 Infection, Hematological Malignancies	10/22	10/22
CLARITY, NCT03190525: Clinical Decision-making, Prognosis, Quality of Life and Satisfaction in Relapsed/Refractory Multiple Myeloma	Recruiting	N/A	520	Europe	Quality of life questionnaires	Gruppo Italiano Malattie EMatologiche dell'Adulto	Multiple Myeloma	12/24	12/24

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Tosi, Patrizia
SELECT MDS-1, NCT04797780 / 2020-004528-40: Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome	Terminated	3	246	Europe, Canada, US, RoW	Tamibarotene, SY-1425, Placebo, Azacitidine	Syros Pharmaceuticals	Myelodysplastic Syndromes	11/24	11/24
KRdvsRd, NCT04096066: A Trial That Compare Two Treatments in Newly Diagnosed Myeloma Patients Not Eligible for Transplant	Active, not recruiting	3	84	Europe	Carfilzomib, Kyprolis, Lenalidomide, Revlimid, Dexamethasone	Fondazione EMN Italy Onlus	Multiple Myeloma, New Diagnosis Tumor	01/26	01/26
DREAMM 14, NCT05064358 / 2021-004151-16: Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma Jul 2024 - Dec 2024 : Data for RRMM	Active, not recruiting	2	177	Europe, Canada, US, RoW	Belantamab mafodotin	GlaxoSmithKline	Multiple Myeloma	08/24	01/26
AL-TOMICA, NCT06626893: Integrative "Omics" Approaches for Leukemia Target Identification and Matched Therapeutic Intervention	Recruiting	N/A	100	Europe	Functional tests, Next Generation Sequencing analysis, Microvesicles analysis	Azienda Ospedaliero-Universitaria di Parma	Myeloid Leukemia, Acute, Leukemia, Acute Lymphoblastic	03/25	03/25
NCT04352556: COVID19-hematological Malignancies: the Italian Hematology Alliance	Recruiting	N/A	250	Europe		Ospedale di Circolo - Fondazione Macchi	SARS-CoV-2 Infection, Hematological Malignancies	10/22	10/22
CLARITY, NCT03190525: Clinical Decision-making, Prognosis, Quality of Life and Satisfaction in Relapsed/Refractory Multiple Myeloma	Recruiting	N/A	520	Europe	Quality of life questionnaires	Gruppo Italiano Malattie EMatologiche dell'Adulto	Multiple Myeloma	12/24	12/24